Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $21.80.
Several research firms recently issued reports on CLBT. DA Davidson upped their price objective on Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, Needham & Company LLC decreased their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th.
Get Our Latest Research Report on CLBT
Cellebrite DI Stock Up 3.6%
Insider Activity at Cellebrite DI
In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the transaction, the chief executive officer owned 590,777 shares in the company, valued at $9,310,645.52. This represents a 14.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 158,191 shares of company stock valued at $2,479,438 over the last ninety days. Insiders own 5.70% of the company’s stock.
Institutional Trading of Cellebrite DI
A number of large investors have recently made changes to their positions in CLBT. Elevation Wealth Partners LLC bought a new position in Cellebrite DI during the second quarter valued at approximately $44,000. Moody National Bank Trust Division boosted its holdings in Cellebrite DI by 7.6% in the second quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock worth $886,000 after purchasing an additional 4,284 shares during the last quarter. Pacer Advisors Inc. grew its position in Cellebrite DI by 91.1% in the 1st quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock worth $105,000 after purchasing an additional 3,626 shares during the period. Alpine Woods Capital Investors LLC bought a new stake in Cellebrite DI in the 1st quarter worth approximately $223,000. Finally, Evolutionary Tree Capital Management LLC raised its stake in Cellebrite DI by 22.6% during the 1st quarter. Evolutionary Tree Capital Management LLC now owns 183,473 shares of the company’s stock valued at $2,528,000 after buying an additional 33,829 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors.
Cellebrite DI Company Profile
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
Featured Stories
- Five stocks we like better than Cellebrite DI
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
